Editas Medicine, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Editas Medicine, Inc. (NASDAQ: EDIT) is a clinical-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing transformative genomic medicines using CRISPR/Cas9 and CRISPR/Cas12a gene editing platforms to treat serious diseases, including rare genetic disorders, hyperlipidemia, ocular diseases, blood disorders, and cancers. The company offers a pipeline of in vivo and ex vivo gene editing therapies, such as EDIT-401, an investigational in vivo medicine targeting the LDLR gene via upregulation to achieve over 90% mean reduction in LDL-cholesterol levels in preclinical non-human primate studies; hematopoietic stem cell editing programs for non-malignant hematological diseases; and engineered cell therapies including CD19-directed allogeneic CAR-T programs for autoimmune diseases and oncology in collaboration with partners. Editas Medicine operates primarily in the United States with corporate headquarters in Cambridge, Massachusetts, and additional facilities in Boulder, Colorado, while advancing global clinical trials and partnerships. Founded in 2013 as Gengine, Inc. and renamed Editas Medicine shortly thereafter, the company targets patient populations underserved by existing therapies, including those with high cholesterol resistant to standard lipid-lowering drugs, through one-time, durable treatments delivered via lipid nanoparticles and other modalities. Recent developments include the nomination of EDIT-401 as a lead in vivo development candidate in September 2025, with proof-of-concept data presented at the European Society of Gene and Cell Therapy Congress in October 2025 and the American Heart Association Scientific Sessions in November 2025, demonstrating sustained LDL-C reductions; discontinuation of the reni-cel program in 2024 to prioritize in vivo efforts, incurring a $12.2 million restructuring charge; extension of its strategic collaboration with Bristol Myers Squibb in May 2024 for autologous and allogeneic alpha-beta T cell therapies targeting cancer and autoimmune diseases, including first IND/CTA acceptance for a CD19 HD Allo CAR-T program that triggered a milestone payment in 2025; and a October 2024 partnership with Genevant Sciences providing non-exclusive access to lipid nanoparticle technology for in vivo gene editing medicines against two undisclosed targets, valued at up to $238 million in milestones plus royalties.
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
Editas Medicine Announces Proposed Public Offering
Editas Medicine Announces Proposed Public Offering
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
Editas Medicine Announces First Quarter 2026 Results and Business Updates
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of “Moderate Buy” from Analysts
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?
JPMorgan Chase & Co. Has $2.85 Million Position in Editas Medicine, Inc. $EDIT
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Rating of “Moderate Buy” from Analysts
Is Editas Medicine Going to $0?
Editas Medicine, Inc. (EDIT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript